John Kheir

OmniOx is a biotechnology company developing a novel class of intravenous oxygen delivery agents designed to treat severe hypoxemia and prevent organ damage during critical medical emergencies. Based on the research of Dr. John Kheir at Boston Children's Hospital, the company's platform utilizes gas-filled lipid microparticles that can be injected directly into the bloodstream to rapidly restore oxygen levels when the lungs are unable to function. This technology aims to provide a bridge to recovery for patients suffering from cardiac arrest, acute respiratory distress syndrome, or severe lung injury. By bypassing the pulmonary system, OmniOx's therapeutic approach offers a potential life-saving intervention for conditions where traditional ventilation is insufficient.